Oculis Holding AG Overview
Pro stress-test →Oculis is a global biopharmaceutical company focused on saving sight and improving eye care, with a highly differentiated pipeline comprising multiple innovative product candidates including OCS-01 for diabetic macular edema and post-cataract surgery inflammation, OCS-02 for dry eye disease, and OCS-05 for acute optic neuritis. Headquartered in Switzerland with operations in the U.S. and Iceland, the company addresses significant unmet medical needs in ophthalmology and neuro-ophthalmology.
Strategic Profile
Pro stress-test →Oculis leverages proprietary OPTIREACH® solubilizing formulation technology to enable eye drops to effectively reach the back of the eye, providing a technical differentiation in the ophthalmology sector. The company is advancing OCS-01 in Phase 3 for DME, initiating Licaminlimab's Predict 1 trial, and progressing Privosegtor's PIONEER program for acute optic neuritis, positioning it as a late-stage clinical pipeline player targeting significant commercial opportunities.
Competitive Landscape
Pro stress-test →Oculis competes in the ophthalmology/neuro-ophthalmology therapeutic space against larger pharma companies and specialized biotech firms. Key competitive areas include: DME treatment (Novartis, Roche, Regeneron), dry eye disease (Allergan, Sun Pharma, Aldeyra), and optic neuritis/neuroprotection (early-stage competitors). Oculis' OPTIREACH technology and topical formulation approach provide differentiation against traditional systemic or invasive therapies.
Industry Context
Oculis Holding AG operates in Biopharmaceutical - Ophthalmology & Neuro-Ophthalmology.
Key facts
Founded: 2017 · Headquarters: Zug, Switzerland · Revenue: CHF 686K (2024) · Market cap: N/A